论文部分内容阅读
目的观察替普瑞酮联合埃索美拉唑、阿莫西林三联疗法治疗幽门螺旋杆菌(Hp)相关性消化性溃疡的临床疗效。方法选择Hp相关性消化性溃疡患者60例,将其随机分为观察组和对照组各30例。观察组给予替普瑞酮联合埃索美拉唑及阿莫西林治疗,对照组给予埃索美拉唑和阿莫西林及安慰剂治疗。8周后比较2组临床疗效和Hp根除率。结果观察组总有效率和Hp根除率均高于对照组(P<0.05)。结论胃黏膜保护剂替普瑞酮联合质子泵抑制剂埃索美拉唑及阿莫西林三联疗法可明显提高Hp相关性消化性溃疡的疗效,值得临床推广应用。
Objective To observe the clinical efficacy of teprenone combined with esomeprazole and amoxicillin triple therapy in the treatment of peptic ulcer associated with Helicobacter pylori (Hp). Methods Sixty patients with Hp-related peptic ulcer were selected and randomly divided into observation group and control group with 30 cases each. The observation group was treated with teprenone plus esomeprazole and amoxicillin, and the control group with esomeprazole and amoxicillin and placebo. After 8 weeks, the clinical efficacy and Hp eradication rate were compared between the two groups. Results The total effective rate and Hp eradication rate in the observation group were higher than those in the control group (P <0.05). Conclusion Gastric mucosal protective agent teprenone combined with proton pump inhibitor esomeprazole and amoxicillin triple therapy can significantly improve the efficacy of Hp-related peptic ulcer, worthy of clinical application.